Prudential Financial Inc. grew its stake in shares of Array Biopharma Inc (NASDAQ:ARRY) by 14.9% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 173,911 shares of the biopharmaceutical company’s stock after purchasing an additional 22,594 shares during the period. Prudential Financial Inc. owned approximately 0.08% of Array Biopharma worth $8,058,000 at the end of the most recent reporting period.
Other large investors also recently bought and sold shares of the company. Alpha Windward LLC purchased a new position in Array Biopharma in the 2nd quarter valued at approximately $28,000. Cornerstone Advisors Inc. raised its stake in shares of Array Biopharma by 38.2% during the 1st quarter. Cornerstone Advisors Inc. now owns 2,226 shares of the biopharmaceutical company’s stock worth $54,000 after buying an additional 615 shares during the last quarter. Advisory Services Network LLC acquired a new position in shares of Array Biopharma during the 1st quarter worth $84,000. Spearhead Capital Advisors LLC acquired a new position in shares of Array Biopharma during the 2nd quarter worth $202,000. Finally, World Asset Management Inc purchased a new stake in shares of Array Biopharma in the 2nd quarter worth about $230,000.
Shares of NASDAQ ARRY remained flat at $$47.85 during midday trading on Wednesday. The stock has a market capitalization of $10.68 billion, a price-to-earnings ratio of -65.55 and a beta of 1.70. Array Biopharma Inc has a 1 year low of $12.56 and a 1 year high of $47.98. The company has a debt-to-equity ratio of 0.45, a quick ratio of 5.65 and a current ratio of 5.70. The company’s 50-day moving average price is $47.77 and its 200-day moving average price is $34.14.
About Array Biopharma
Array BioPharma Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer and other diseases in North America, Europe, and the Asia Pacific. It provides BRAFTOVITM (encorafenib) capsules in combination with MEKTOVI (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAF mutation.
Further Reading: What is Cost of Goods Sold (COGS)?
Receive News & Ratings for Array Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Array Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.